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In chronic haemodialysis patients, anaemia is a frequent finding associated with high therapeutic costs and further expenses
resulting from serial laboratory measurements. HemoHue HH1, HemoHue Ltd, is a novel tool consisting of a visual scale for
the noninvasive assessment of anaemia by matching the coloration of the conjunctiva with a calibrated hue scale. The aim of the
study was to investigate the usefulness of HemoHue in estimating individual haemoglobin concentrations and binary treatment
outcomes in haemodialysis patients. A prospective blinded study with 80 hemodialysis patients comparing the visual haemoglobin
assessment with the standard laboratory measurement was performed. Each patient’s haemoglobin concentration was estimated
by seven different medical and nonmedical observers with variable degrees of clinical experience on two different occasions. The
estimated population mean was close to the measured one (11.06± 1.67 versus 11.32± 1.23 g/dL, 𝑃 < 0.0005). A learning effect could
be detected. Relative errors in individual estimates reached, however, up to 50%. Insufficient performance in predicting binary
outcomes (ROC AUC: 0.72 to 0.78) and poor interrater reliability (Kappa < 0.6) further characterised this method.
1. Introduction
Anaemia is a feature commonly encountered in dailymedical
practice especially in well-defined clinical subpopulations
such as nephrologic, oncologic, or pediatric patients. Diagno-
sis and therapeuticmonitoring of anaemia are based on blood
sampling and laboratory measurements, both necessitating
the presence of qualified personnel, logistic, and technical
resources and generate high costs especially if repetitive
measurements are required. This is particularly striking
when considering end-stage renal disease patients treated
with recombinant human erythropoietin (rHuEPO) [1]. The
imperative to reach and stay within a narrow haemoglobin
concentration target range [2, 3], the peculiar pharmacoki-
netic and pharmacodynamic properties of rHuEPO [4–8],
making its use difficult even in hands of experienced nephro-
logists, has led to the general acceptance of systematic and
frequentmonitoring of the haemoglobin concentration levels
during therapy with rHuEPO.
Although in developed countries laboratory facilities are
easily accessible, the availability of a simple, cheap, noninva-
sive, and reproducible bedside method to assess the degree of
anaemia in patients necessitating serial measurements would
be very suitable [9, 10].
Severe anaemia may be detected by the naked-eye in the
presence of significant skin pallor, pale nail beds and palms,
whereas the examination of the conjunctiva provides in gen-
eral a more sensitive and accurate estimation independent of
the skin pigmentation [9–13]. However, this method remains
crude and largely observer-dependent since the intensity of
the conjunctiva colour is not matched with a reference hue
[10].
The HemoHue HH1 device (HemoHue Ltd) consists of a
credit card-like small tool with an imprinted red hue con-
sisting in seven red spots with increasing colour inten-
sity matched with increasing haemoglobin concentrations
(Figure 1).s
o
u
r
c
e
:
 
ht
tp
:/
/b
or
is
.u
ni
be
.c
h/
17
48
7/
 
| 
do
wn
lo
ad
ed
: 
8.
5.
20
16
2 Anemia
Figure 1: HemoHue HH1, HemoHue Ltd. Credit card sized device
with an imprinted red hue, corresponding Hb levels, and a white
luminescent control spot.
The aim of the present prospective, comparative, and
blinded study was to assess the validity of the HemoHue
HH1 device in detecting and scaling the degree of anaemia
in chronic haemodialysis patients. Eventual effects of an
increased observer practice, formation, and general char-
acteristics such as age and gender, on estimation of the
haemoglobin concentrationwere evaluated.The ability of this
new method in correctly detecting patients’ haemoglobin
concentrations inside and outside the therapeutic range was
also assessed.
2. Subjects and Methods
2.1. Patients. Eighty chronic haemodialysis patients from our
dialysis ward were enrolled in the study. Inclusion criteria
were age over eighteen and capacity to understand the aim
of the study and to give verbal consent. Any of the following
excluded the patient from participating in study: acute or
chronic affection of the anterior segment of the eye and the
unavailability of a laboratory measurement of haemoglobin
within twoweeks of the visual assessment or the presence of a
clinically relevant bleeding and/or transfusion requirements.
The study was approved by the local ethics committee
board, Kantonale Ethikkommission Bern, Universita¨t Bern,
Switzerland.
2.2. Study Design and Methods. Patients were assessed in
decubitus or semidecubitus position on the dialysis chair
within the first two hours of their usual treatment session.
Localization of the patient in the dialysis room in relation to
the natural light intensity (next to the window, intermediary,
next to the door), the day time, and the ultrafiltration per-
formed at the time of measurement was recorded. Two com-
mercially available polychromatic neon tubes providing nat-
ural light, fixed perpendicularly on a rolling tripod, were
used to ensure optimal lighting conditions as indicated by the
whitening of the control luminescent spot on the HemoHue
HH1 card.
The visual estimation of the haemoglobin concentration
was performed as follows: the inferior lid was retracted, and
the most intensely colored spot of the conjunctival sack was
compared with the colored spots on the HemoHue HH1 card
and matched. This procedure was repeated independently
by all seven observers: one medical student (med stud), one
dialysis nurse (nurse), three physicians with increasing age
and degree of clinical experience (phys A, phys B, and phys
C), and two administrative employees (desk A and desk B).
The sequence in which the estimations were performed was
randomized each time. Every observer was blinded for the
estimates of all coobservers and the measured haemoglobin
values during the whole study.
The procedure mentioned above was repeated on two
nonconsecutive haemodialysis sessions at a two-week inter-
val (1st and 2nd session). In the meantime, the laboratory
measurement of haemoglobin was performed in all subjects
at the beginning of a haemodialysis session, hence providing
one individual reference value. Some observers participated
to both sessions and were, therefore, considered to be skilled
as opposed to those who assisted only punctually to the first
or the second session (novice).
2.3. Statistics. The software package Systat 12 (SPSS Inc.,
Chicago, IL) and R.2.8.1 (R Development Core Team) were
used for statistical analyses and graphical presentation. Val-
ues are given as mean ± standard deviation (SD) if not
indicated otherwise. Intergroup analysis was performed by
one-way ANOVA with Bonferroni post-hoc analysis. The
package “irr” v. 0.7 (R Development Core Team) was used
to compute the Cohen’s and Fleiss’ Kappa test [14] for the
interobserver reliability. The overall agreement between the
visual and the standard method was assessed with the Bland-
Altman plot [15].
According to our preliminary statistical analysis, 68
patients were necessary to reject the null hypothesis in dis-
criminating between bothmethods (measured haemoglobin-
estimated haemoglobin concentration = ±5 g/L) to reach a
power of 90% at a significance level of 5%.
3. Results
From the initially evaluated 80 patients during the first
session, 75 were still available for visual estimations during
the second session. Five dropouts were recorded (3 absences
and 2 missing laboratory data). Patient characteristics are
summarized in Table 1.
3.1. Pooled Data Analysis. The estimated population mean
was close to the measured one (11.06 ± 1.67 versus 11.32 ±
1.23 g/dL, 𝑃 < 0.0005), and the slight underestimation could
be improved during the second session as indicated by the
reduced absolute residuals (estimated and measured Hb
concentration, 1st session versus 2nd session: −0.47 ± 0.07
versus −0.06 ± 0.07 g/dL, 𝑃 < 0.0005).
The analysis of the Bland-Altman plots (mean of esti-
mated and measured haemoglobin values versus absolute
residuals consisting of estimated and measured values) pro-
vided further information concerning the performance of
this method (Figure 2). As may be easily seen from these
plots, a poor agreement between the estimated and the
measured values was found, highlighting a clear systematic
error (misspecification) with underestimation in the low con-
centration range and overestimation in the higher range. In
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Figure 2: Bland-Altman plot highlighting the results of the first (a) and second (b) session. On the𝑋-axis, is plotted themean of themeasured
and estimated Hb values. The absolute residuals (estimated and measured) are plotted on the 𝑌-axis. The plain line represents the mean
residual, the mean ±1.96 ∗ SD is represented by the dotted lines, respectively.
Table 1: Patients characteristics (pooled sessions) (𝑁 = 80 on 1st session and𝑁 = 75 on 2nd session).
Age, years 66.0 ± 14.4 (70∗)
Race, white versus black 76 : 4
Gender, male versus female 47 : 33
Measured hemoglobin level, g/dL 11.32 ± 1.23 (11.3∗) 𝑄
25–75 = [10.6; 12.1]
Estimated haemoglobin level, g/dL (pooled) 11.06 ± 1.67 (11.0∗) 𝑄
25–75 = [10.0; 12.0] 𝑄25–75 = [10.21; 12.00]
†
Values are mean ± SD.
∗Indicates the median.
†Quartiles based on the mean of all observers per patient.
accordance with the previous statement, the linear regression
performed on pooled values yielded a rather flat line with a
high intercept: [Hb]Measured = 0.302 ⋅ [Hb]Estimated +7.984 in
[g/dL]; 𝑅 = 0.1692, 𝑃 < 0.001. Further, for the same meas-
ured value, very high dispersion of the estimates could be
noticed with relative error reaching nearly 50%.
3.2. Interobserver Differences and Multivariate Analysis. Di-
chotomizing the observers into two groups: medical student
and physicians (physicians) versus nurse and administrative
employees (nonphysicians) permitted to show an improved
accuracy of the estimate in the physicians versus the nonphysi-
cians group (ΔResidual = 0.626 g/dL, 𝑃 < 0.0005). Skilled
observers gave a more accurate estimation of Hb concen-
trations as compared with novices (ΔResidual = 0.341 g/dL,
𝑃 < 0.001). Crossing both categories provided further sig-
nificant results for all subcategories with the exception of the
“physicians × skilled” versus “physicians × novice” pair.
Cofactors interfering with the lighting conditions such as
the position of the patient in the dialysis room in relation to
the windows or the day time did not influence significantly
the accuracy of the estimates. The same was observed if the
estimates were corrected by the actual amount of ultrafiltra-
tion at the time of measurement. A trend towards better esti-
mates in younger patients with presumed less degenerative
conjunctival affections (<40 years) compared to older ones
(>80 years) (+0.032 versus −0.544 g/dL, 𝑃 = 0.064) as well as
the providing of higher estimates by the two last observers
due to the hyperthermic effect of the manipulation on the
conjunctiva (observers [1–5] versus observers [6, 7]) (−0.327
versus −0.127 g/dL, 𝑃 = 0.066) were noted. The correction
with the confounding factor (observer) failed, however, in
achieving the significance level. The gender of the patients
and the observers was not associated with any difference in
the accuracy of the estimates.
3.3. Test Specificities and Interrater Agreement in Binary Out-
comes. Besides the aptitude of the HemoHue HH1 tool to
improve visual estimation of individual haemoglobin val-
ues, we, furthermore, tested its performance in providing
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Figure 3: Receiver operating characteristic (ROC) curves for detecting anaemia at different cutoff values. First versus second session with
corresponding haemoglobin concentration cutoff values and ROC AUC (a). Physicians versus nonphysicians and corresponding ROC AUC
(b).
Table 2: Test specificities in detecting binary outcomes.
Outcome Sens. Spec. PPV NPV Kappa Sens. Spec. PPV NPV Kappa
1st session 2nd session
Hb < 10 g/dL 50 73 29 89 0.34 33 92 38 91 0.29
10 g/dl ≤Hb ≤ 12 g/dL 53 48 60 42 0.22 74 56 70 62 0.31
Hb > 12 g/dL 39 91 58 82 0.45 65 87 71 83 0.46
Physicians Non-physicians
Hb < 10 g/dL 32 87 29 88 0.44 55 76 29 90 0.39
10 g/dL ≤Hb ≤ 12 g/dL 64 51 64 51 −0.01 59 46 60 45 −0.04
Hb > 12 g/dL 63 86 63 86 0.58 35 89 54 79 0.41
Sensitivity, specificity, and positive and negative predictive values are given in percents.
estimation of binary treatment outcomes. According to
KDOQI guidelines, the therapeutic haemoglobin target for
rHuEPO treated patients should be in the range of 11.0 to
12.0 g/dL [2, 16]. Since the proposed range is very narrow and
reaches the discrimination limit of theHemoHueHH1 device
of ±1 g/dL, we arbitrarily defined the outcomes (undertreat-
ment) as a haemoglobin concentration below 10 g/dL, (within
therapeutic range) as a haemoglobin concentration between
10 and 12 g/dL, respectively, whereas (overtreatment) was set
above 12 g/dL. In Table 2, the test specificities (sensitivity,
specificity, positive and negative predictive values) and the
interobserver agreement (reliability) in detecting the three
scenarios described above are shown. As may be easily seen,
the predictive performance of the method was slightly better
at extreme haemoglobin values, especially in correctly reject-
ing undertreatment, without reaching, however, the standards
to qualify as a good screening test.These findings are visually
summarizedwith the receiver operating characteristic (ROC)
curves in Figure 3. Furthermore, the reported values across
subgroups (1st versus 2nd session, physician versus non-
physician) were not substantially different. A slight to mod-
erate interobserver agreement (reliability) for the outcome
undertreatment and overtreatment could be noted (Kappa’s
ranging from 0.29 to 0.58), whereas a striking poor reliability
could be observed for the within therapeutic range outcome.
4. Discussion
To our knowledge, this is the first clinical trial which sys-
tematically assesses the validity of the novel visual bedside
tool HemoHue HH1 for the estimation of haemoglobin con-
centration in chronic haemodialysis patients.
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Despite its simple use as a noninvasive and inexpensive
test, convincing theoretical aspects and practical experience
from previous clinical trials, this study clearly demonstrated
the poor performance of the HemoHue HH1 tool in predict-
ing visually the actual haemoglobin concentration in dialysis
patients. This failure is evidenced by (1) the inability to
estimate the actual haemoglobin level accurately based on
one-observer guess, (2) no further consistent improvement
of the accuracy when averaging the estimates of different
observers, and finally (3) poor performance in estimating the
binary treatment outcomes.
Although the estimated populationmeanwas rather close
to the measured populationmean, individual estimates (one-
observer estimation of one patient value) were crude with
relative error ranging up to 50%. Further, as pointed out by
the Bland-Altmanplot, the presence of a systematic errorwith
underestimation in lowerHb range and overestimation in the
higher range was found.
In the analysis of variance, a leaning effect with decreased
residuals during the second session could be detected. The
same feature was seen when comparing skilled with novice
observers. It appears, however, improbable that this effect
could be further substantially extendedwith practice. Assum-
ing that the provided estimation is a sumof the true estimated
value and an error which is largely due to interobserver
discrimination aptitude, increasing the number of raters
per item, should theoretically improve the precision of the
estimates by lowering the noise component due to the error.
However, this approach is hampered by the relative poor gain
in accuracy over the individual approach and the difficulties
in clinical implementation.
The estimation of the binary treatment outcomes was also
characterized by an overall poor performance, especially by a
very poor interobserver agreement in the therapeutic range.
The test specificities for binary outcomes at the haemoglobin
level of 11 g/dL were comparable with those described in pre-
vious works in nonnephrologic patients [10, 11].
There are different possible explanations of this failure.
First, the achieved haemoglobin values in this particular
population are within a narrow therapeutic range of 1 to
2 g/dL. When considering the density plot of the measured
haemoglobin values, most of the patients were within the
therapeutic range of 11 to 12 g/dL. The HemoHue HH1 device
based on a visual estimation with a discrimination power of
1 g/dL could be not precise enough in this setting.
Further, the inclusion of nephrologists aware of treatment
goals and outcomes provides certainly a bias. The analysis
of the density plots of the estimated values shows a narrow
curve centred at known treatment targets in nephrologists.
The curves in nonmedical staff were more dispersed about
the theoreticalmean and left skewed (tendency to provide low
values). This may be underlined by the fact that there was no
statistically significant difference in estimates between skilled
and novice medical observers.
On the other side, our study population consisting prin-
cipally of aged, chronic haemodialysis patients with some
degree of degenerative ocular affection and vascular dys-
function could account in part for the discrepancy between
the estimated and the measured haemoglobin level. So far,
the visual anaemia evaluation was principally assessed and
validated in paediatric and gynaecologic patients as a raw
screening test. Although not significant, a trend toward
decreased accuracy of the estimates in older patients was
noted.
There are several limitations to this study including
among others the lack of a real training component. Indeed,
the observers in our study were neither aware of real results
nor could they train themselves against reference values.
However, the effect of training on the use of the HemoHue
HH1 reference card for the visual estimation of hemoglobin
values was not the aim of this study. As a matter of fact, the
study was designed to prevent a carryover effect of education
on the outcome by not providing the testers with a feedback
on their performance. According to the manufacturer, the
device can be used even by untrained people and still produce
good results provided that adequate lighting conditions are
fulfilled as indicated by the whitening of the control spot. In
otherwords, appropriate estimationwould have been ensured
by the correct matching of the hue between the card and
the conjunctiva, primary implicating skills in discriminating
colors, rather than by conditioning the response of the
observer with a reference value.
Finally, training observers against reference values in the
dialysis setting would have been impracticable. The time
required to obtain laboratory results is much too long to per-
mit the required simultaneous comparison since time delay
may preclude correct estimation due to hemoconcentration
induced by ultrafiltration during the dialysis procedure.
When we designed the study, available preliminary data
clearly confirmed the superiority of the HemoHue HH1 ref-
erence card over the naked-eye estimation, and we assumed
to achieve a comparable increase in accuracy in hemodialysis
patients.
Despite undeniable further improvement in estimating
visually the haemoglobin level as compared with the crude,
naked-eye assessment, this method failed in estimating with
acceptable accuracy the individual haemoglobin level as well
as the individual binary treatment outcomes. The validity
of these findings should be, however, limited to the studied
particular haemodialysis population and not preclude the
further deployment and validation of this method in other
clinical groups.
5. Conclusions
Despite undeniable additional improvement in estimating
visually the haemoglobin levels as compared with the crude,
naked-eye assessment, this method failed in predicting with
acceptable accuracy the individual haemoglobin level as well
as the individual binary treatment outcomes.
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